According to the top 10 most co-cited articles (Table 6), LANCET’s “ Lenvatinib versus sorafenib in first-line treatment of patients with unresectable HCC: a randomized phase 3 noninferiority trial,” the first author of the article is Kudo M, which is based on a phase 2 trial in which levatinib, an inhibitor of VEGFR 1 to 3, FGFR 1 to 4, PDGF receptor a, RET and KIT, showed activity against HCC. Here, RET is linked to hepatocellular carcinoma.